50 Years Forward
To celebrate our golden anniversary, we commissioned a group of innovative and provocative commentaries looking 50 years into the future. When we invited writers to contribute we encouraged them to hypothesise and conceptualise, challenging them to embrace ‘blue sky, left field, out of the box thinking’! The articles were then peer reviewed and are now part of this special edition.
Creative use of novel glucose-lowering drugs for type 2 diabetes
Bo Ahrén
The erosion of physical activity in Western societies: an economic death march
Frank Booth and John Hawley
50 years forward: beta cells
Philippe Halban
Hepatokines: unlocking the multi-organ network in metabolic diseases
Alison Iroz, Jean-Pierre Couty and Catherine Postic
Medications for type 2 diabetes: how will we be treating patients in 50 years?
Steven E. Kahn and John B. Buse
Genomic medicine at the heart of diabetes management
Mark I. McCarthy
Incretin-based therapies: where will we be 50 years from now?
Juris J. Meier, Michael A. Nauck
Future of muscle research in diabetes: a look into the crystal ball
Michael Roden
50 years forward: mechanisms of hyperglycaemia-driven diabetic complications
Nicholas D. F. Russell, Mark E. Cooper
Vascular AGE-ing by methylglyoxal: the past, the present and the future
Casper G. Schalkwijk
The future of brown adipose tissues in the treatment of type 2 diabetes
Patrick Schrauwen, Wouter D. van Marken Lichtenbelt, Bruce M. Spiegelman